Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation

Melanoma Research

Volumn 16, Issue 2, 2006, Pages 165-174

  Wankowicz Kalinska, Anna ^a,b   Mailliard, Robbie B ^a   Olson, Kathleen ^a   Graham, Fiona ^a   Edington, Howard ^a,c   Kirkwood, John M ^a,c   Martinek, Stephanie ^a   Das, Pranab K ^b   Storkus, Walter J ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

CD8+ T cells; ELISPOT; Leucoderma; Melanocortin receptor 1; Melanoma

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; HLA DR4 ANTIGEN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 1 RECEPTOR PEPTIDE [105-118]; MELANOCORTIN 1 RECEPTOR PEPTIDE [120-132]; MELANOCORTIN 1 RECEPTOR PEPTIDE [149-161]; MELANOCORTIN 1 RECEPTOR PEPTIDE [188-197]; MELANOCORTIN 1 RECEPTOR PEPTIDE [196-215]; MELANOCORTIN 1 RECEPTOR PEPTIDE [235-247]; MELANOCORTIN 1 RECEPTOR PEPTIDE [251-259]; MELANOCORTIN 1 RECEPTOR PEPTIDE [255-268]; MELANOCORTIN 1 RECEPTOR PEPTIDE [52-60]; MELANOCORTIN 1 RECEPTOR PEPTIDE [61-73]; MELANOCORTIN 1 RECEPTOR PEPTIDE [82-95]; MELANOCORTIN 1 RECEPTOR PEPTIDE [99-107]; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CASE REPORT; CELL INFILTRATION; CELL ISOLATION; CELL STIMULATION; DEPIGMENTATION; EFFECTOR CELL; HISTOINCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKODERMA; MALE; MELANOMA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKIN DEFECT; T LYMPHOCYTE; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HYPOPIGMENTATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPH NODE METASTASIS; MELANOCYTE; METABOLISM; METASTASIS; PARANEOPLASTIC SYNDROME; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR;

ADULT; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HUMANS; HYPOPIGMENTATION; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MELANOCYTES; MELANOMA; PARANEOPLASTIC SYNDROMES; PROGNOSIS; RECEPTOR, MELANOCORTIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 33745917391     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000198452.03957.73     Document Type: Article

References (34)

1. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9:689-696.
2. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res 2003; 16:254-260.
3. Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993; 11:536-538.
4. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-182.
5. Wakamatsu K, Graham A, Cook D, Thody AJ. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res 1997; 10:288-297.
6. Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, Serrano A, et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 2002; 87:414-422.
7. Bohm M, Metze D, Schulte U, Becher E, Luger TA, Brzoska T. Detection of melanocortin-1 receptor antigenicity on human skin cells in culture and in situ. Exp Dermatol 1999; 8:453-461.
8. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996; 137:1627-1633.
9. Kadekaro AL, Kanto H, Kavanagh R, Abdel-Malek ZA. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann NY Acad Sci 2003; 994:359-365.
10. Thody AJ. α-MSH and the regulation of melanocyte function. Ann NY Acad Sci 1999; 885:217-229.
11. Loir B, Perez Sanchez C, Ghanem G, Lozano JA, Garcia-Borron JC, Jimenez-Cervantes C. Expression of the MC1 receptor gene in normal and malignant human melanocytes. A semiquantitative RT-PCR study. Cell Mol Biol 1999; 45:1083-1092.
12. Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997; 57:4348-4355.
13. Maurer D, Gorski J. Transfer of polymorphic monoclonal antibody epitopes to the first and second domains of HLA-DR beta-chains by site-directed mutagenesis. J Immunol 1991; 146:621-626.
14. Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das PK. Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80:1299-1309.
15. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002; 88:136-146.
16. Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24:3038-3043.
17. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J Immunol 2001; 167:787-796.
18. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 2000; 97:400-405.
19. Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, et al. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells. Br J Cancer 2001; 85:1738-1745.
20. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, et al. MAGE-6 encodes HLA-DRβ1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003; 9:947-954.
21. Wankowicz-Kalinska A, van den Wijngaard RMJGJ, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, et al. Immunopolarization of CD4+ and CD8+ cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83:683-695.
22. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3:221-226.
23. Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997; 203:141-152.
24. Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151:3719-3727.
25. Sturm RA. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 2002; 12:405-416.
26. Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991; 16:303-305.
27. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123:1053-1055.
28. Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, et al. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol 2003; 121:308-314.
29. Wang X, Erf GF. Apoptosis in feathers of Smyth line chickens with autoimmune vitiligo. J Autoimmunity 2004; 22:21-30.
30. Sherman LA, Theobald M, Morgan D, Hernandez J, Bacik I, Yewdell J, et al. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit Rev Immunol 1998; 18:47-54.
31. Funasaka Y, Chakraborty AK, Hayashi Y, Komoto M, Ohashi A, Nagayama M, et al. Modulation of melanocyte-stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin-1α, interleukin 1-β, endothelin-1 and tumor necrosis factor-α. Br J Dermatol 1998; 139:216-224.
32. Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RV, Gawkrodger DJ, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109:923-930.
33. Sanchez Mas J, Olivares Sanchez C, Ghanem G, Haycock J, Lozano Teruel JA, Garcia-Borron J, et al. Loss-of-function variants of the human melanocortin-1 receptor gene in melanoma cells define structural determinants of receptor function. Eur J Biochem 2002; 269:6133-6141.
34. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294-230.